A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Study sponsor: UroGen Pharma Ltd. · URGN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-03-17Actual
Enrollment · participants282Actual
Source updated2024-06-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.